Context Therapeutics Inc. (CNTX) Misses Q3 EPS by 1c

Context Therapeutics Inc. (NASDAQ: CNTX) reported Q3 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09).

For earnings history and earnings-related data on Context Therapeutics Inc. (CNTX) click here.

You May Also Be Interested In

• FDA approves Revolution Medicines pancreatic cancer drug Rasonque
• Amazon's AWS to acquire DuckLabs, maker of DuckDB database
• Meta to pay $18 billion over 10 years for youth online safety initiatives.